DURECT’s (DRRX) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of DURECT (NASDAQ:DRRX) in a report released on Thursday,Benzinga reports.

Separately, StockNews.com began coverage on DURECT in a research report on Monday, November 11th. They set a “sell” rating on the stock.

DURECT Stock Down 9.8 %

Shares of NASDAQ:DRRX opened at $1.01 on Thursday. The company has a market cap of $31.35 million, a price-to-earnings ratio of -1.66 and a beta of 1.13. DURECT has a fifty-two week low of $0.48 and a fifty-two week high of $1.88. The firm’s 50-day simple moving average is $1.35 and its 200-day simple moving average is $1.37.

Hedge Funds Weigh In On DURECT

A number of large investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after buying an additional 14,658 shares in the last quarter. Richmond Brothers Inc. grew its holdings in shares of DURECT by 39.5% in the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after acquiring an additional 303,670 shares during the period. International Assets Investment Management LLC increased its stake in DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares in the last quarter. Accredited Investors Inc. acquired a new position in DURECT during the second quarter worth $113,000. Finally, Gagnon Securities LLC boosted its position in DURECT by 6.0% during the first quarter. Gagnon Securities LLC now owns 380,131 shares of the specialty pharmaceutical company’s stock worth $460,000 after purchasing an additional 21,425 shares in the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.